26. (Original) A method of treatment or prevention of allergic rhinitis, allergic conjunctivitis, eosinophilic granuloma, osteoporosis, arterial restenosis, atherosclerosis, reperfusion injury of the myocardium chronic glomerulonephritis, vernal conjunctivitis, cachexia, transplant rejection, or graft versus host disease, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

27. (Original) A method of treatment or prevention of depression, memory impairment, monopolar depression, Parkinson disease, Alzheimer's disease, acute and chronic multiple sclerosis, psoriasis, benign or malignant proliferative skin diseases, atopic dermatitis, urticaria, cancer, tumour growth or cancerous invasion of normal tissues, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

28. (Original) A method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of compound of claim 1.

29. (Presently Amended) A method of enhancing cognition in a healthy subject comprising administering a safe, non-emetic, cognition enhancing amount of compound of claim 1.

30. (Original) A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 40 years of age or older.

31. (Original) A method of enhancing cognition in a healthy subject according to claim 28, wherein the healthy subject is a human 55 years of age or older.

REMARKS

Claim 1 to 31 are pending in this application. Claims 1 to 23 have been allowed. Claims 24 to 31 have been rejected.

At the middle of page 2 of the Office Action, the Examiner rejects Claim 29 under 35 USC 112 second paragraph. The claim fails to provide the number of the claim on which it depends. In response applicants have amended the claim to indicate that it depends on claim 1.

Support for this amendment is found in the detailed description, for example bridging pages 34 and 35.

Beginning at the bottom of page 2 of the Office Action, the Examiner rejects claim 24 under 35 USC 112, first paragraph. The Examine asserts that the instant specification does not adequately describe the leukotreine receptor antagonist, leukotreine biosynthesis inhibitor or M2/M3 antagonist which might be combined wit the instantly claimed invention. While applicants respectfully traverse, they have nonetheless canceled claim 24 in order to advance the prosecution of this application. Applicants reserve the right to prosecute the canceled subject matter in a continuing or divisional application.

At the middle of page 3 of the Office Action, the Examiner rejects method of treatment Claims 25-31 under 35 USC 112, first paragraph for failing to comply with the enablement. The Examiner relies, at least in part, on the assertion that:

The presence or absence of working examples: Many examples of assays that could rest for the activity being claimed are described by the instant specification. However, no assays have been performed. The specification only describes what could be done and what the activity could treat or prevent.

Applicants respectfully traverse and direct the Examiner's attention to the results summarized at page 38, line 25 and 26; and page 39, lines 31 and 32. In addition, applicants hereby submit references discussing various utilities for PDE 4 inhibitors. Applicants have also added an additional method of treatment claim in order to advance the prosecution of this application.

Having addressed the outstanding rejections, applicants respectfully submit that the application is in condition for allowance and passage thereto is earnestly requested. The Examiner is invited to contact the undersigned attorney if such would advance the prosecution of this application.

Respectfully submitted,

By _____

Curtis C. Panzer
Reg. No. 33,752
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(908) 594-3199

Date: April 24, 2006